Viewing Study NCT00086658


Ignite Creation Date: 2025-12-25 @ 12:12 AM
Ignite Modification Date: 2026-02-24 @ 10:55 AM
Study NCT ID: NCT00086658
Status: COMPLETED
Last Update Posted: 2020-05-05
First Post: 2004-07-07
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Sponsor: GlaxoSmithKline
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hypereosinophilia View
None Hypereosinophilic Syndrome View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Hypereosinophilic Syndrome Hypereosinophilia View
None mepolizumab View
None anti IL-5 View